Stock Track | HealthEquity Soars 5.09% in Pre-market on Strong Q2 Results and Raised Guidance

Stock Track

Sep 03, 2025

Shares of HealthEquity (HQY) surged 5.09% in pre-market trading on Wednesday following the company's impressive second-quarter fiscal 2026 results and raised full-year guidance. The leading provider of Health Savings Account (HSA) custodial services in the United States continues to demonstrate strong financial performance and strategic growth.

HealthEquity reported a 9% year-over-year increase in revenue, reaching $325.8 million for Q2. More notably, the company's net income jumped by 67% to $59.9 million, while adjusted earnings per share came in at $1.08, marking a 26% increase from the previous year. The robust financial results were driven by solid asset growth, cost improvements, and a strategic focus on digital adoption and security measures.

Following these strong results, HealthEquity's management raised its full-year guidance for fiscal 2026. The company now projects revenue between $1.290 billion and $1.310 billion, with adjusted EBITDA expected to range from $540 million to $560 million. This optimistic outlook has further fueled investor confidence in the stock.

Analysts have responded positively to HealthEquity's performance, with several firms maintaining their buy ratings and raising price targets. JPMorgan analyst Alexei Gogolev increased the firm's price target to $126 from $125, while maintaining an Overweight rating. The average analyst price target now stands at $121.93, reflecting the market's bullish sentiment on HealthEquity's growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1172190996"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172190996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172190996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172190996","market":"sg","top_or_hot":-1,"title":"Stock Track | HealthEquity Soars 5.09% in Pre-market on Strong Q2 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of HealthEquity (HQY) surged 5.09% in pre-market trading on Wednesday following the company's impressive second-quarter fiscal 2026 results and raised full-year guidance. The leading provider of Health Savings Account (HSA) custodial services in the United States continues to demonstrate strong financial performance and strategic growth.</p>\n\n<p>HealthEquity reported a 9% year-over-year increase in revenue, reaching $325.8 million for Q2. More notably, the company's net income jumped by 67% to $59.9 million, while adjusted earnings per share came in at $1.08, marking a 26% increase from the previous year. The robust financial results were driven by solid asset growth, cost improvements, and a strategic focus on digital adoption and security measures.</p>\n\n<p>Following these strong results, HealthEquity's management raised its full-year guidance for fiscal 2026. The company now projects revenue between $1.290 billion and $1.310 billion, with adjusted EBITDA expected to range from $540 million to $560 million. This optimistic outlook has further fueled investor confidence in the stock.</p>\n\n<p>Analysts have responded positively to HealthEquity's performance, with several firms maintaining their buy ratings and raising price targets. JPMorgan analyst Alexei Gogolev increased the firm's price target to $126 from $125, while maintaining an Overweight rating. The average analyst price target now stands at $121.93, reflecting the market's bullish sentiment on HealthEquity's growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HealthEquity Soars 5.09% in Pre-market on Strong Q2 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HealthEquity Soars 5.09% in Pre-market on Strong Q2 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-03 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of HealthEquity (HQY) surged 5.09% in pre-market trading on Wednesday following the company's impressive second-quarter fiscal 2026 results and raised full-year guidance. The leading provider of Health Savings Account (HSA) custodial services in the United States continues to demonstrate strong financial performance and strategic growth.</p>\n\n<p>HealthEquity reported a 9% year-over-year increase in revenue, reaching $325.8 million for Q2. More notably, the company's net income jumped by 67% to $59.9 million, while adjusted earnings per share came in at $1.08, marking a 26% increase from the previous year. The robust financial results were driven by solid asset growth, cost improvements, and a strategic focus on digital adoption and security measures.</p>\n\n<p>Following these strong results, HealthEquity's management raised its full-year guidance for fiscal 2026. The company now projects revenue between $1.290 billion and $1.310 billion, with adjusted EBITDA expected to range from $540 million to $560 million. This optimistic outlook has further fueled investor confidence in the stock.</p>\n\n<p>Analysts have responded positively to HealthEquity's performance, with several firms maintaining their buy ratings and raising price targets. JPMorgan analyst Alexei Gogolev increased the firm's price target to $126 from $125, while maintaining an Overweight rating. The average analyst price target now stands at $121.93, reflecting the market's bullish sentiment on HealthEquity's growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HQY","symbol_name":"HealthEquity","start_time":0,"source_url":"","article_id":"1172190996","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172190996","pubTimestamp":1756902502,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of HealthEquity (HQY) surged 5.09% in pre-market trading on Wednesday following the company's impressive second-quarter fiscal 2026 results and raised full-year guidance. The leading provider...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HQY":"HealthEquity"},"translate_title":"个股追踪|HealthEquity盘前大涨5.09%，Q2业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HQY":1},"content_text":"Shares of HealthEquity (HQY) surged 5.09% in pre-market trading on Wednesday following the company's impressive second-quarter fiscal 2026 results and raised full-year guidance. The leading provider of Health Savings Account (HSA) custodial services in the United States continues to demonstrate strong financial performance and strategic growth.\nHealthEquity reported a 9% year-over-year increase in revenue, reaching $325.8 million for Q2. More notably, the company's net income jumped by 67% to $59.9 million, while adjusted earnings per share came in at $1.08, marking a 26% increase from the previous year. The robust financial results were driven by solid asset growth, cost improvements, and a strategic focus on digital adoption and security measures.\nFollowing these strong results, HealthEquity's management raised its full-year guidance for fiscal 2026. The company now projects revenue between $1.290 billion and $1.310 billion, with adjusted EBITDA expected to range from $540 million to $560 million. This optimistic outlook has further fueled investor confidence in the stock.\nAnalysts have responded positively to HealthEquity's performance, with several firms maintaining their buy ratings and raising price targets. JPMorgan analyst Alexei Gogolev increased the firm's price target to $126 from $125, while maintaining an Overweight rating. The average analyst price target now stands at $121.93, reflecting the market's bullish sentiment on HealthEquity's growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}